Guo Qian, Zhong Xinxin, Dang Zihan, Zhang Baiquan, Yang Zixin
Department of Rhinology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
School of Integrative Medicine, Nanjing University of Chinese Medicine, No. 138, Xianlin Road, Qixia District, Nanjing, Jiangsu, China.
Discov Oncol. 2025 Jan 25;16(1):85. doi: 10.1007/s12672-025-01840-9.
We conducted a panoramic analysis of GBN5 expression and prognosis in 33 cancers, aiming to deepen the systematic understanding of GBN5 in cancer.
We employed a multi-omics approach, including transcriptomic, genomic, proteomic, single-cell cytomic, spatial transcriptomic, and genomic data, to explore the prognostic value and potential oncogenic mechanisms of GBN5 across pan-cancers from multiple perspectives.
We found that GBN5 was differentially expressed in multiple tumors and showed early diagnostic value. Mutations, somatic copy number alterations, and DNA methylation lead to its aberrant expression. GBN5 expression is associated with many clinical features. GBN5 expression has been validated to be associated with many metabolic, metastatic, and immune-related pathways. We also demonstrated that GBN5 expression was significantly associated with immunomodulatory molecules and biomarkers of lymphocyte subpopulation infiltration. Methylation levels of GBN5 expression were significantly negatively correlated in a variety of tumors, and GBN5 missense mutations were the predominant SNP type in pan-cancer. In addition, GBN5 was positively correlated with multiple genomic scores, implying that higher GBN5 expression tends to imply that patients have higher chromosomal instability. More importantly, GBN5 has an important role in predicting drug sensitivity. We have also developed effective targeted drugs against GBN5.
GBN5 plays an important role in the genesis and progression of various tumors and is a potential tumor diagnostic and prognostic biomarker as well as an anti-cancer therapeutic target.
我们对33种癌症中的GBN5表达和预后进行了全景分析，旨在加深对GBN5在癌症中系统的理解。
我们采用了多组学方法，包括转录组学、基因组学、蛋白质组学、单细胞细胞组学、空间转录组学和基因组数据，从多个角度探索GBN5在泛癌中的预后价值和潜在致癌机制。
我们发现GBN5在多种肿瘤中差异表达，并具有早期诊断价值。突变、体细胞拷贝数改变和DNA甲基化导致其异常表达。GBN5表达与许多临床特征相关。GBN5表达已被证实与许多代谢、转移和免疫相关途径有关。我们还证明GBN5表达与免疫调节分子和淋巴细胞亚群浸润的生物标志物显著相关。GBN5表达的甲基化水平在多种肿瘤中显著负相关，并且GBN5错义突变是泛癌中主要的单核苷酸多态性类型。此外，GBN5与多个基因组评分呈正相关，这意味着较高的GBN5表达往往意味着患者具有较高的染色体不稳定性。更重要的是，GBN5在预测药物敏感性方面具有重要作用。我们还开发了针对GBN5的有效靶向药物。
GBN5在各种肿瘤的发生和发展中起重要作用，是一种潜在的肿瘤诊断和预后生物标志物以及抗癌治疗靶点。
